Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8445-8458

  Xie, Yuanchao ^a   Xu, Dongqing ^a   Huang, Bing ^b   Ma, Xiuli ^b   Qi, Wenbao ^c   Shi, Fangyuan ^a   Liu, Xinyong ^a   Zhang, Yingjie ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PEANUT RESEARCH INSTITUTE   (China)

^c SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 3 (PENTAN 3 YLOXY) 5 (1 PENTYLGUANIDINO)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE; 4 ACETAMIDO 3 (PENTAN 3 YLOXY) 5 (1 PROPYLGUANIDINO)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 3 (PENTAN 3 YLOXY) 5 [(THIOPHEN 2 YLMETHYL)AMINO]CYCLOHEX 1 ENECARBOXYLIC ACID ACETATE SALT; 4 ACETAMIDO 3 (PENTAN 3 YLOXY) 5 [1 (3 PHENYLPROPYL)GUANIDINO]CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 3 (PENTAN 3 YLOXY) 5 [1 (THIOPHEN 2 YLMETHYL)GUANIDINO]CYLOHEX 1 ENECARBOXYLIC ACID TRIFLUOROACETATE SALT; 4 ACETAMIDO 5 (1 BENZYLGUANIDINO) 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 (1 BUTYLGUANIDINO) 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 (1 ISOBUTYLGUANIDINO) 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 (1 ISOPENTYLGUANIDINO) 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 (BENZYLAMINO) 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 (BUTYLAMINO) 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID ACETATE SALT; 4 ACETAMIDO 5 (CINNAMYLAMINO) 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID; 4 ACETAMIDO 5 (ISOBUTYLAMINO) 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID ACETATE SALT; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; 4 ACETAMIDO 5 AMINO N HYDROXY 3 (PENTAN 3YLOXY)CYCLOHEX 1 ENECARBOXAMIDE HYDROCHLORIDE; 4 ACETAMIDO 5 GUANIDINO 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 [(2 BROMOBENZYL)AMINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 [(2 CHLOROBENZYL)AMINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID ACETATE SALT; 4 ACETAMIDO 5 [(2 FLUOROBENZYL)AMINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 [(2 HYDROXYBENZYL)AMINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID; 4 ACETAMIDO 5 [(2 METHOXYBENZYL)AMINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE; 4 ACETAMIDO 5 [(2-ETHYLBUTYL)AMINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID; 4 ACETAMIDO 5 [1 (2 ETHYLBUTYL)GUANIDINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE SALT; 4 ACETAMIDO 5 [1 (2 METHOXYBENZYL)GUANIDINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLUOROACETATE SALT; 4 ACETAMIDO 5 [1 (4 ISOPROPYLBENZYL) GUANIDINO] 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACTATE SALT; 5 [1 [(1,1 ' BIPHENYL) 4 YLMETHYL]GUANIDINO] 4 ACETAMIDO 3 (PENTAN 3 YLOXY)CYCLOHEX 1 ENECARBOXYLIC ACID TRIFLOUROACETATE; INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE; VIRUS PROTEIN;

ARTICLE; BINDING SITE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; IC50; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MOLECULAR DOCKING; PROTON NUCLEAR MAGNETIC RESONANCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIVIRAL AGENTS; BINDING SITES; CHEMISTRY TECHNIQUES, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INHIBITORY CONCENTRATION 50; MOLECULAR DOCKING SIMULATION; NEURAMINIDASE; OSELTAMIVIR; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

EID: 84908389455     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500892k     Document Type: Article

References (31)

1. Girard, M. P.; Tam, J. S.; Assossou, O. M.; Kieny, M. P. The 2009 A (H1N1) influenza virus pandemic: a review Vaccine 2010, 28, 4895-4902
2. Uyeki, T. M.; Cox, N. J. Global concerns regarding novel influenza A (H7N9) virus infections N. Engl. J. Med. 2013, 368, 1862-1864
3. Stevens, J.; Blixt, O.; Chen, L. M.; Donis, R. O.; Paulson, J. C.; Wilson, I. A. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity J. Mol. Biol. 2008, 381, 1382-1394
4. Nguyen, H. T.; Nguyen, T.; Mishin, V. P.; Sleeman, K.; Balish, A.; Jones, J.; Creanga, A.; Marjuki, H.; Uyeki, T. M.; Nguyen, D. H.; Nguyen, D. T.; Do, H. T.; Klimov, A. I.; Davis, C. T.; Gubareva, L. V. Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011 Emerging Infect. Dis. 2013, 19, 1963-1971
5. Samson, M.; Pizzorno, A.; Abed, Y.; Boivin, G. Influenza virus resistance to neuraminidase inhibitors Antiviral Res. 2013, 98, 174-185
6. Dapat, C.; Kondo, H.; Dapat, I. C.; Baranovich, T.; Suzuki, Y.; Shobugawa, Y.; Saito, K.; Saito, R.; Suzuki, H. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan Antiviral Res. 2013, 99, 261-269
7. Memoli, M. J.; Hrabal, R. J.; Hassantoufighi, A.; Eichelberger, M. C.; Taubenberger, J. K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts Clin. Infect. Dis. 2010, 50, 1252-1255
8. Russell, R. J.; Haire, L. F.; Stevens, D. J.; Collins, P. J.; Lin, Y. P.; Blackburn, G. M.; Hay, A. J.; Gamblin, S. J.; Skehel, J. J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design Nature 2006, 443, 45-49
9. Cheng, L. S.; Amaro, R. E.; Xu, D.; Li, W. W.; Arzberger, P. W.; McCammon, J. A. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase J. Med. Chem. 2008, 51, 3878-3894
10. D'Ursi, P.; Chiappori, F.; Merelli, I.; Cozzi, P.; Rovida, E.; Milanesi, L. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase Biochem. Biophys. Res. Commun. 2009, 383, 445-449
11. Li, Y.; Zhou, B.; Wang, R. Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1 J. Mol. Graphics Modell. 2009, 28, 203-219
12. Du, Q. S.; Wang, S. Q.; Chou, K. C. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus Biochem. Biophys. Res. Commun. 2007, 362, 525-531
13. Landon, M. R.; Amaro, R. E.; Baron, R.; Ngan, C. H.; Ozonoff, D.; McCammon, J. A.; Vajda, S. Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble Chem. Biol. Drug Des. 2008, 71, 106-116
14. Garcia-Sosa, A. T.; Sild, S.; Maran, U. Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant J. Chem. Inf. Model. 2008, 48, 2074-2080
15. Liu, K. C.; Fang, J. M.; Jan, J. T.; Cheng, T. J.; Wang, S. Y.; Yang, S. T.; Cheng, Y. S.; Wong, C. H. Enhanced anti-influenza agents conjugated with anti-inflammatory activity J. Med. Chem. 2012, 55, 8493-8501
16. Adabala, P. J.; LeGresley, E. B.; Bance, N.; Niikura, M.; Pinto, B. M. Exploitation of the catalytic site and 150 cavity for design of influenza A neuraminidase inhibitors J. Org. Chem. 2013, 78, 10867-10877
17. Kongkamnerd, J.; Cappelletti, L.; Prandi, A.; Seneci, P.; Rungrotmongkol, T.; Jongaroonngamsang, N.; Rojsitthisak, P.; Frecer, V.; Milani, A.; Cattoli, G.; Terregino, C.; Capua, I.; Beneduce, L.; Gallotta, A.; Pengo, P.; Fassina, G.; Miertus, S.; De-Eknamkul, W. Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus Bioorg. Med. Chem. 2012, 20, 2152-2157
18. Schade, D.; Kotthaus, J.; Riebling, L.; Muller-Fielitz, H.; Raasch, W.; Koch, O.; Seidel, N.; Schmidtke, M.; Clement, B. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A J. Med. Chem. 2014, 57, 759-769
19. Mohan, S.; McAtamney, S.; Haselhorst, T.; von Itzstein, M.; Pinto, B. M. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles J. Med. Chem. 2010, 53, 7377-7391
20. Rudrawar, S.; Dyason, J. C.; Rameix-Welti, M. A.; Rose, F. J.; Kerry, P. S.; Russell, R. J.; van der Werf, S.; Thomson, R. J.; Naffakh, N.; von Itzstein, M. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase Nat. Commun. 2010, 1, 113-119
21. Feng, E.; Shin, W. J.; Zhu, X.; Li, J.; Ye, D.; Wang, J.; Zheng, M.; Zuo, J. P.; No, K. T.; Liu, X.; Zhu, W.; Tang, W.; Seong, B. L.; Jiang, H.; Liu, H. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors J. Med. Chem. 2013, 56, 671-684
22. Lin, C. H.; Chang, T. C.; Das, A.; Fang, M. Y.; Hung, H. C.; Hsu, K. C.; Yang, J. M.; von Itzstein, M.; Mong, K. K.; Hsu, T. A.; Lin, C. C. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities Org. Biomol. Chem. 2013, 11, 3943-3948
23. Mooney, C. A.; Johnson, S. A.; 't Hart, P.; Quarles van Ufford, L.; de Haan, C. A.; Moret, E. E.; Martin, N. I. Oseltamivir analogues bearing N-substituted guanidines as potent neuraminidase inhibitors J. Med. Chem. 2014, 57, 3154-3160
24. Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P. A.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors J. Med. Chem. 1998, 41, 2451-2460
25. Shie, J. J.; Fang, J. M.; Wang, S. Y.; Tsai, K. C.; Cheng, Y. S.; Yang, A. S.; Hsiao, S. C.; Su, C. Y.; Wong, C. H. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity J. Am. Chem. Soc. 2007, 129, 11892-11893
26. Govorkova, E. A.; Leneva, I. A.; Goloubeva, O. G.; Bush, K.; Webster, R. G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses Antimicrob. Agents Chemother. 2001, 45, 2723-2732
27. Liu, Y.; Zhang, J.; Xu, W. Recent progress in rational drug design of neuraminidase inhibitors Curr. Med. Chem. 2007, 14, 2872-2891
28. Collins, P. J.; Haire, L. F.; Lin, Y. P.; Liu, J. F.; Russell, R. J.; Walker, P. A.; Skehel, J. J.; Martin, S. R.; Hay, A. J.; Gamblin, S. J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants Nature 2008, 453, 1258-1262
29. Liu, A. L.; Wang, H. D.; Lee, S. M.; Wang, Y. T.; Du, G. H. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities Bioorg. Med. Chem. 2008, 16, 7141-7147
30. Bi, W.; Cai, J.; Liu, S.; Baudy-Floc'h, M.; Bi, L. Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates Bioorg. Med. Chem. 2007, 15, 6909-6919
31. Hanson, S. K.; Wu, R.; Silks, L. A. Mild and selective vanadium-catalyzed oxidation of benzylic, allylic, and propargylic alcohols using air Org. Lett. 2011, 13, 1908-1911